Market report
Pharmaceutical tenders in Poland — market report, September 2025
Pharmaceutical tenders in Poland in September 2025: 712 tenders published (+130% month on month, +64% year on year), estimated at €111,929,976 in total, and 3,556 contracts awarded (-10% month on month, -18% year on year), worth €538,380,884 (awarded value). Buyers with the most tenders: Uniwesytecki Szpital Kliniczny w Poznaniu (14), Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie spółka z ograniczoną odpowiedzialnością (11) and Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy (9); most contracts won: Farmacol-Logistyka Sp. z o.o. (319), Asclepios S.A. (291) and Urtica Sp. z o.o. (121). On average 1.8 bids per contract; 60% of contracts had a single bid. Report made on 27 October 2026.
- Tenders published
- 712
- Contracts awarded
- 3,556
- Contract value awarded
- €538,380,884
- Bids per contract
- 1.8
The highlighted bar is September 2025. Hover a bar for its figure; the table below has every value.
| Figure | September 2025 | August 2025 | Change | September 2024 | Change |
|---|---|---|---|---|---|
| Tenders published | 712 | 309 | +130% | 434 | +64% |
| Estimated value | €111,929,976 | €37,126,339 | +201% | €81,742,897 | +37% |
| Buyers | 170 | 165 | +3% | 210 | -19% |
| Contracts awarded | 3,556 | 3,951 | -10% | 4,360 | -18% |
| Contract value (awarded) | €538,380,884 | €478,235,157 | +13% | €327,050,695 | +65% |
| Winners | 154 | 147 | +5% | 156 | -1% |
| Bids per contract | 1.8 | 1.9 | — | 1.8 | — |
| Single-bid contracts | 60% | 56% | — | 57% | — |
Buyers with the most tenders
Companies with the most contracts
| # | Winners | Contracts |
|---|---|---|
| 1 | Farmacol-Logistyka Sp. z o.o. | 319 |
| 2 | Asclepios S.A. | 291 |
| 3 | Urtica Sp. z o.o. | 121 |
| 4 | Komtur Polska Sp. z o.o. | 111 |
| 5 | Salus International Sp. z o.o. | 55 |
| 6 | Amgen Sp. z o.o. | 52 |
| 7 | Abbvie Sp. z o.o. | 40 |
| 8 | Fagron Sp. z o.o. | 39 |
| 9 | Takeda Pharma Sp. z o.o. | 36 |
| 10 | Delfarma Sp. z o.o. | 34 |
Where the tenders were
Procedures
The report's aggregates: the figures, the comparisons and the top lists by name and count.
All reports: Medicines and pharmaceuticals
Questions and answers
- How many pharmaceutical tenders were published in Poland in September 2025?
- 712 (by 170 buyers); for comparison, August 2025: 309, September 2024: 434.
- Who won the most pharmaceutical tenders in Poland in September 2025?
- By number of contracts: Farmacol-Logistyka Sp. z o.o. (319), Asclepios S.A. (291), Urtica Sp. z o.o. (121), Komtur Polska Sp. z o.o. (111) and Salus International Sp. z o.o. (55); 154 companies won contracts in all.
- Which buyers published the most pharmaceutical tenders in September 2025?
- Uniwesytecki Szpital Kliniczny w Poznaniu (14), Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie spółka z ograniczoną odpowiedzialnością (11), Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy (9), Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi (8) and Uniwersytecki Szpital Dziecięcy w Krakowie (6).
- How competitive were pharmaceutical tenders in Poland in September 2025?
- On average 1.8 bids per contract (791 contracts with a known number of bids); 60% of contracts had a single bid.
- What were the contracts worth in September 2025?
- €538,380,884 (awarded value, 3,556 contracts); median about €17,000.
How the report is made
Tenders published: the tenders of the sector or topic whose first notice is dated in the month (a tender counts in its sector and in up to three topics). Contracts awarded: the awards dated in the month, whenever their tender was published. Values in EUR, by value kind (never added together); medians are approximate (±3 %). Comparisons: with the reports of the previous month and of the same month a year earlier, each made the same way. The report was made on 27 October 2026 from the data of that day and is not changed afterwards; sources publish late, so later data for the month are not in it.